With Integration of Biovail Nearly Completed, Valeant Looks For More Deals In 2011
This article was originally published in The Pink Sheet Daily
Executive SummaryValeant's price-conscious, opportunistic approach to business development and relentless pace of activity has enabled it to quadruple sales in three years and grow its top-line 7% in 2010.
You may also be interested in...
Even as private equity firms reach into specialty pharma niche opportunities for deals, specialty pharma companies are evolving, as well. Valeant Pharmaceuticals is a very visible example of one kind of specialty pharma model, which is based as much upon sophisticated financial engineering as product growth.